| Previous Close | 1.43 |
| Open | 1.44 |
| Day High | 1.53 |
| Day Low | 1.41 |
| 52-Week High | 1.81 |
| 52-Week Low | 0.64 |
| Volume | 1.42M |
| Average Volume | 840,745 |
| Market Cap | 151.71M |
| PE | -4.9 |
| EPS | -0.3 |
| Moving Average 50 Days | 1.22 |
| Moving Average 200 Days | 1.06 |
| Change | 0.04 |
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery
GlobeNewswire Inc.
Feb 24, 2026 1:05 PM GMT
ROCKVILLE, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cel
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
GlobeNewswire Inc.
Feb 23, 2026 9:05 PM GMT
ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cel
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
GlobeNewswire Inc.
Jan 12, 2026 1:05 PM GMT
ROCKVILLE, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-gen